Atlantic Equities analyst Steve Chesney maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $220 to $295.
Zevia Shares Soar On Better-Than-Expected Q2 Top-Line Performance
Zevia PBC (NYSE:ZVIA) reported second-quarter FY22 sales growth of 33% year-on-year to $45.54 million, beating the consensus of $42.17 million. Unit…
